RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia

Area of Science:

• Oncology
• Genetics
• Epigenetics

Background:

• Juvenile myelomonocytic leukemia (JMML) is an aggressive childhood cancer.
• Existing markers do not fully capture JMML's diverse clinical and biological features.
• RAS signaling pathway mutations are key drivers in JMML.

Purpose of the Study:

• To investigate the molecular heterogeneity of JMML.
• To identify novel subgroups within JMML based on DNA methylation and mutation profiles.
• To correlate molecular subtypes with clinical outcomes and genetic alterations.

Main Methods:

• DNA methylome analysis of 167 JMML patient samples.
• Comprehensive mutation profiling of JMML samples.
• Correlation of molecular data with clinical characteristics and patient prognosis.

Main Results:

• Identification of three distinct JMML subgroups: high (HM), intermediate (IM), and low methylation.
• HM group associated with PTPN11 mutations and poor prognosis.
• Low methylation group linked to NRAS/CBL mutations, Noonan syndrome, and good prognosis.
• IM group characterized by monosomy 7 and KRAS mutations.
• Hypermethylation linked to repressed chromatin, RAS-regulated genes, and DNMT1/DNMT3B upregulation.

Conclusions:

• DNA methylation patterns define distinct JMML subgroups with unique molecular and clinical features.
• These findings suggest a link between DNA methylation machinery activation and specific mutational patterns in JMML.
• Subgroup identification may improve JMML diagnosis, prognosis, and therapeutic strategies.